REGENERATIVE MEDICINE CROSSING BORDERS

Launch of FIRST investment fund to accelerate development of solutions for prevention and cure of chronic diseases ensuring patients benefit earlier

On February 13, during the Innovation for Health 2020 conference in Rotterdam, Focco Vijselaar, Director-General for Business and Innovation of the Ministry of Economic Affairs and Climate Policy, officially launched the ‘Fonds InvesteringsRijpe STarters’ (FIRST).

FIRST is a joint early phase investment fund of the Dutch CardioVascular Alliance (DCVA) and Regenerative Medicine Crossing Borders (RegMed XB) with a total volume of 9.5 million euros. The ministry is investing 5.5 million euros in the project, the DCVA and RegMed XB both invest 2 million euros. In addition to the FIRST fund, the partners invest in expert guidance for researchers to bring knowledge obtained by their research to patients. For this purpose, the ministry is investing an additional 2.5 million euros.

This initiative is important for Dutch patients, because of the gap that is still often found in translating results from fundamental medical research into available solutions, such as a new treatment or innovative technology. The various partners involved in the DCVA and RegMed XB have worked together to ensure that researchers receive support in taking the first step towards bringing their findings to the market.

The DCVA and RegMed XB are public-private partnerships that bring together the best researchers in the Netherlands in patient-driven development of new solutions aimed at preventing and curing chronic diseases such as cardiovascular disease, kidney disease, diabetes and osteoarthritis. Together with university "knowledge transfer offices", the DCVA and RegMed XB are actively scouting for such solutions to help with the plans, team formation and initial technical and clinical evidence needed to attract other investors.

FIRST finances this first development into an "investment-ready" company based on proposals of sufficient quality and potential. The fund has an independent investment manager and committee and is managed by BioGeneration Ventures, one of the most successful venture capital firms investing in (the early phase of) European life sciences companies. After the launch, FIRST is working hard to start a first investment round this summer.

Focco Vijselaar, Director-General for Business and Innovation of the Ministry of Economic Affairs and Climate Policy

 

From left to right: Rianne Ellenbroek, Investment Manager; Marianne van der Steen, General Director Regmed XB; Edward van Wezel, Managing Partner BioGeneration Ventures; Rob de Ree, DCVA Chair of valorization and Operating Partner BioGeneration Ventures. This is the team that will lead FIRST pre-seed fund and valorization of Regmed XB and DCVA.

Moments of the RegMed XB General Assembly, Utrecht, February 13, 2020

Moments of the RegMed XB General Assembly, Utrecht, February 13, 2020

Moments of the RegMed XB General Assembly, Utrecht, February 13, 2020

  • Diabetes FondsDiabetes Fonds
  • Leids Universitair Medisch CentrumLeids Universitair Medisch Centrum
  • Provincie UtrechtProvincie Utrecht
  • RijksoverheidRijksoverheid
  • Health HollandHealth Holland
  • Maastricht UMC+Maastricht UMC+
  • Provincie LimburgProvincie Limburg
  • TU/eTU/e
  • NierstichtingNierstichting
  • Provincie Noord-BrabantProvincie Noord-Brabant
  • Universiteit LeidenUniversiteit Leiden
  • LeidenLeiden
  • Stichting DONStichting DON
  • ReumaNederlandReumaNederland
  • Maastricht UniversityMaastricht University
  • UMC UtrechtUMC Utrecht
  • Utrecht UniversityUtrecht University
  • KU LeuvenKU Leuven
  • VIBVIB
  • HartstichtingHartstichting

Copyright © 2017 RegMed XB. All rights reserved | Login
Realisation by JoomlaPartner
Vormgeving Harry de Graaf